Advertisement


James O. Armitage, MD, on Improving Lymphoma Treatment

2016 Pan Pacific Lymphoma Conference

Advertisement

James O. Armitage, MD, of the University of Nebraska Medical Center, discusses how an increased understanding of the biology of lymphomas and their multiple subtypes has had a major impact on the ability to treat patients.



Related Videos

Lymphoma

David G. Maloney, MD, PhD, on Lymphomas: Treatment With CAR T Cells

David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses the efficacy of chimeric antigen receptor (CAR) T cells for lymphoma and their toxicity.

Lymphoma

Steven P. Treon, MD, PhD, on Treating Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia

Steven P. Treon, MD, PhD, of the Dana-Farber Cancer Institute, discusses the question of what is the best upfront therapy for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia.

Lymphoma

Andrew D. Zelenetz, MD, on Diffuse Large B-Cell Lymphoma: CHOP-R and EPOCH-R?

Andrew D. Zelenetz, MD, of Memorial Sloan Kettering Cancer Center, discusses the pros and cons of these two regimens, with or without another agent, in diffuse large B-cell lymphoma.

Lymphoma

Steven M. Horwitz, MD, on Sequencing New Agents in Relapsed Peripheral T-Cell Lymphoma

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, reviews the data supporting current treatment approaches for T-cell lymphomas and discusses the specific subtype criteria used to individualize therapy.

Lymphoma

Richard I. Fisher, MD, on Defining and Treating Grey Zone Lymphoma

Richard I. Fisher, MD, of Fox Chase Cancer Center-Temple Health, discusses this rare disease––with features between classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma––and reviews the clinical data on treatment.

Advertisement

Advertisement




Advertisement